Arbutus Biopharma Files 8-K for Regulation FD Disclosure

Ticker: ABUS · Form: 8-K · Filed: 2024-08-05T00:00:00.000Z

Sentiment: neutral

Topics: regulation-fd, disclosure

TL;DR

Arbutus Biopharma filed an 8-K for a Reg FD disclosure. Details TBD.

AI Summary

Arbutus Biopharma Corp. filed an 8-K on August 5, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of the disclosure, dollar amounts, or other parties involved.

Why It Matters

This filing indicates Arbutus Biopharma is making a public disclosure under Regulation FD, which requires companies to share material information broadly and simultaneously.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure without immediate financial or operational impact detailed.

Key Players & Entities

FAQ

What specific information is being disclosed under Regulation FD?

The filing does not specify the content of the Regulation FD disclosure, only that one is being made.

When was the earliest event reported in this 8-K?

The earliest event reported is August 5, 2024, which is also the date of the report.

What is Arbutus Biopharma Corp.'s principal executive office address?

The address of Arbutus Biopharma Corp.'s principal executive offices is 701 Veterans Circle, Warminster, Pennsylvania 18974.

What is the company's telephone number?

The company's telephone number is (267) 469-0914.

What is the Commission File Number for Arbutus Biopharma Corp.?

The Commission File Number for Arbutus Biopharma Corp. is 001-34949.

From the Filing

0001447028-24-000066.txt : 20240805 0001447028-24-000066.hdr.sgml : 20240805 20240805161303 ACCESSION NUMBER: 0001447028-24-000066 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240805 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20240805 DATE AS OF CHANGE: 20240805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 241174891 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 abus-20240805.htm 8-K abus-20240805 FALSE 0001447028 701 Veterans Circle Warminster Pennsylvania 0001447028 2024-08-05 2024-08-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  August 5, 2024 Arbutus Biopharma Corp oration (Exact name of registrant as specified in its charter)   British Columbia, Canada   001-34949   98-0597776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   701 Veterans Circle Warminster , Pennsylvania   18974 (Address of principal executive offices)   (Zip Code)   ( 267 ) 469-0914 Registrant’s telephone number, including area code     (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Shares, without par value   ABUS   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o Item 7.01. Regulation FD Disclosure. On August 5, 2024 , Arbutus Biopharma Corporation (the “Company”) and its licensee, Genevant Sciences GmbH (“Genevant”), along with Moderna, Inc. (“Moderna”) and a Moderna affiliate filed a Stipulation to Extend Time (the “Stipulation”) with the U.S. District Court for the District of Delaware in the lawsuit brought by t

View on Read The Filing